Austin B. Miller

Generating author description...

All published works

Action	Title	Year	Authors
+	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials	2020	Dario Pasalic Gwendolyn J. McGinnis Clifton D. Fuller Aaron J. Grossberg Vivek Verma W. Ian P. Mainwaring Austin B. Miller Timothy A. Lin Amit Jethanandani Andres F. Espinoza
+ PDF Chat	Assessing the Impact of Complementary and Alternative Medicine Trials in Oncology	2019	Ethan B. Ludmir Amit Jethanandani W. Ian P. Mainwaring Austin B. Miller Timothy A. Lin Andres F. Espinoza Aaron J. Grossberg Clifton D. Fuller

Common Coauthors

Coauthor	Papers Together
W. Ian P. Mainwaring	2
Ethan B. Ludmir	2
Aaron J. Grossberg	2
Amit Jethanandani	2
Clifton D. Fuller	2
Andres F. Espinoza	2
Timothy A. Lin	2
Dario Pasalic	1
Reshma Jagsi	1
Prajnan Das	1
Bruce D. Minsky	1
Charles R. Thomas	1
Adam S. Garden	1
Markus Diefenhardt	1
Claus Rödel	1
Vivek Verma	1
Emmanouil Fokas	1
Ishwaria M. Subbiah	1
Vivek Subbiah	1
Gwendolyn J. McGinnis	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?	2008	Lori E. Dodd Edward L. Korn Boris Freidlin C. Carl Jaffe Larry Rubinstein Janet Dancey Margaret Mooney	1
+ PDF Chat	The misguided ethics of crossover trials	2013	Vinay Prasad Christine Grady	1
+ PDF Chat	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents	2015	Everardo D. Saad Marc Buyse	1
+ PDF Chat	Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials	2015	Caroline S. Bennette Scott D. Ramsey Cara L. McDermott Josh J. Carlson Anirban Basu David L. Veenstra	1
+	Double-Crossed: Why Crossover in Clinical Trials May Be Distorting Medical Science	2013	Vinay Prasad	1
+ PDF Chat	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?	2017	Robert Kemp Vinay Prasad	1
+	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration	2017	Huseyin Naci Katelyn R. Smalley Aaron S. Kesselheim	1
+	Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer	2017	Mahmoud Hashim Boris M. Pfeiffer R. Bartsch Maarten J. Postma Bart Heeg	1
+ PDF Chat	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour	2018	Jianrong Zhang Yiyin Zhang Shiyan Tang Long Jiang Qihua He Lindsey Tristine Hamblin Jiaxi He Zhiheng Xu Jieyu Wu Yaoqi Chen	1
+	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology	2018	Alyson Haslam Spencer Phillips Hey Jennifer Gill Vinay Prasad	1